#oncology #Lilly #LillyOncology #Jaypirca #Pirtobrutinib #primaryendpoint #EliLilly #CLL313 #CLL314 #phase3 #BRUINCLL314trial #chroniclymphocyticleukaemia #CLL #smalllymphocyticlymphoma #SLL #noncovalentBTKinhibitor #Imbruvica #ibrutinib #covalentBTKinhibitor
pharmatimes.com/news/lillys-...
pharmatimes.com/news/lillys-...
Lilly’s Jaypirca shows positive results in phase 3 trial - PharmaTimes
Pirtobrutinib meets primary endpoint in CLL/SLL study
pharmatimes.com
September 9, 2025 at 10:14 AM